A panel of independent experts has decided that alteplase, a clot-busting drug often used to treat strokes is safe and effective under current guidelines.
Published in the journal Stroke, a new study suggests that a drug commonly used to treat rheumatoid arthritis may help reduce harmful inflammation in the brain after stroke. The study was funded by the Stroke Association.
A haemorrhagic stroke is a stroke that is caused by bleeding in or around the brain. Although they are less common than strokes that are caused by a blockage, they can be much more serious.
Promising research results for a new drug treatment for ischaemic stroke patients have been published today in the journal ‘Lancet Neurology’.
Currently, a drug called alteplase is used in thrombolysis, but the researchers think that another drug, called tenecteplase, may be more effective than alteplase.
Led by the University of Nottingham, a new international study investigated whether patients with a spontaneous bleed in the brain (intracerebral haemorrhage) could benefit from this drug, if delivered as an emergency treatment. An intracerebral haemorrhage is a type of stroke.
In stroke survivors, does the clinical effectiveness of 6 months treatment with fluoxetine depend upon its effects on synaptic plasticity in the brain? Can a drug used for depression help stroke recovery by changing connections between brain cells?
Can a drug commonly used for gout improve recovery and prevention of further stroke for stroke survivors?
The CROMIS-2 study investigated whether signs of small brain bleeds on routine brain scans can help us understand which ischaemic stroke patients with atrial fibrillation are at increased risk of a bleed in the brain when on anticoagulant ‘blood thinning’ drugs.
Exploring the effects of lowering blood pressure and a lower dose of clot busting drug on stroke outcome